Navigation Links
Clarus Ventures Names Two New Partners
Date:1/5/2009

Dr. Emmett Cunningham and Scott Requadt Promoted From Principals

CAMBRIDGE, Mass., and SOUTH SAN FRANCISCO, Calif., Jan. 5 /PRNewswire/ -- Clarus Ventures, LLC ("Clarus Ventures"), a leading life sciences venture capital firm, announced today the promotions of Emmett Cunningham, M.D., Ph.D., M.P.H., to Partner and Scott Requadt, J.D., M.B.A., to Transactional Partner, effective Jan. 1, 2009.

Dr. Cunningham joined Clarus in 2006 and represents the firm as a Director on the Board of SARcode and as a Board Observer at FerroKin, Pearl, Taligen and Zogenix. He is also a member of the Scientific Advisory Boards of ESBATech and CoMentis. Dr. Cunningham joined Clarus from Eyetech Pharmaceuticals, where he was Senior Vice President of Medical Strategy and helped build and lead the development and commercialization of Macugen, a first-in-class product for the treatment of age-related macular degeneration. Prior to Eyetech, Dr. Cunningham was at Pfizer, where he was responsible for the clinical development of early-phase CNS compounds and the in-licensing of early- and late-stage therapeutic candidates in ophthalmology.

In addition to his extensive clinical, scientific and operating experience in the pharmaceutical, biotech and medtech industries, Dr. Cunningham is an internationally recognized specialist in eye diseases with more than 200 publications. In addition to his investing responsibilities at Clarus, he is an Adjunct Clinical Professor of Ophthalmology at Stanford. Dr. Cunningham received his M.D. and M.P.H. degrees from Johns Hopkins University and his Ph.D. degree in neuroscience from the University of California at San Diego. He completed his residency in ophthalmology and his fellowship training in corneal disease and uveitis at the University of California, San Francisco.

"Emmett has demonstrated a superior understanding of a wide
'/>"/>

SOURCE Clarus Ventures, LLC
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Clarus Ventures Closes $660 Million Fund
2. Hank Plain Joins Morgenthaler Ventures as Partner
3. Dan Broderick Joins Prolog Ventures as Partner
4. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
5. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
6. Khosla Ventures and BIOeCON Form KiOR Inc.
7. Jerusalem Global Ventures Announces $200 Million Growth Equity Fund
8. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
9. The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C.
10. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
11. SPO Medical Retains American Capital Ventures for Investor Relations Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... 2013 The JM Internet Group (web: ... has proudly announced that the company's YouTube channel on ... 175,000 views on YouTube. The company uses YouTube as ... tips and training for small businesses with much success. ... YouTube tips helpful for their SEO strategies", explained Jason ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Dr. Sparano ... and Women’s Health at the Albert Einstein College of ... at the Montefiore Medical Center. He is also ... Center and leads the Einstein Breast Cancer Working Group, ... translational breast cancer research. He also serves as Vice ...
(Date:5/17/2013)... transplant recipient,s immune system identifies the transplanted organ as ... that T cells, the immune cells that mediate rejection, ... in order to migrate to the transplanted organ. In ... , Fadi Lakkis and colleagues at the University of ... T cells is not required for migration. Instead, these ...
(Date:5/17/2013)... 17, 2013 - Elsevier, a world-leading provider of scientific, ... the publication of a recent study in ... blastocysts showing that those with an abnormal chromosomal composition ... have developed to blastocysts, thereby classifying the risk of ... the same group has undertaken a retrospective study, using ...
Breaking Biology Technology:YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3Breakthrough for IVF? 2Breakthrough for IVF? 3
... and the public agree that the promise of nanotechnology is ... be governed accordingly. , The new technology, which is ... to computers, is seen differently among scientists than the general ... areas. But in broad categories of risk versus reward both ...
... N.Y., Feb. 15 EUSA Pharma (Oxford, UK), ... licensed OP-R003,a human anti-interleukin-6 antibody discovered by Vaccinex, ... product license, GSK will pay an up-front,license fee, ... the exclusive world-wide rights to develop and commercialize,OP-R003 ...
... Data presented at the 2008 Genitourinary Cancers ... OncoGenex Technologies Inc. announced,today that the Company,s ... as custirsen, was well-tolerated in combination with ... in patients with,hormone refractory prostate cancer. Additionally, ...
Cached Biology Technology:Nanotech's health, environmental impacts worry scientists and the public 2Nanotech's health, environmental impacts worry scientists and the public 3Vaccinex Antibody Licensed to GlaxoSmithKline 2OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer 2OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer 3OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer 4
(Date:5/19/2013)... reports that white men and women of European descent ... and lesser toe deformities, including hammer or claw toe. ... the heritability of foot disorders in humansappear in ... Wiley on behalf of the American College of Rheumatology ... as 60% of older adults have foot disorders which ...
(Date:5/18/2013)... Research presented at Digestive Disease Week (DDW) explores ... and lifestyle. , Individuals suffering from Crohn,s ... fatigue and poor quality of life. These symptoms ... A randomized, double blind, placebo-controlled study found for ... to significant relief of these symptoms. , ...
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
Breaking Biology News(10 mins):Blame your parents for bunion woes 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3First Atlanta Science Festival set for 2014 2
... may emerge from a laboratory model that has just been ... human immune stem cells from umbilical cord blood into mice ... live alongside the mouse,s own immune system. Although mice ... causes typhoid fever, the bacteria are able to reproduce in ...
... Md. (September 22, 2010) The National Science Foundation ... Science Chesapeake Biological Laboratory $1.7 million to repair and ... Since 1936, the pier has played an instrumental role ... on climate change, fisheries management and the health of ...
... The antibacterial ingredient in some soaps, toothpastes, odor-fighting socks, ... long-sought new treatment for a parasitic disease that affects ... became the guiding light for future development of drugs ... Medicinal Chemistry . In the study, Rima McLeod ...
Cached Biology News:Humanized mice may provide clues to better prevent and treat typhoid fever 2Humanized mice may provide clues to better prevent and treat typhoid fever 3UMCES Chesapeake Biological Laboratory to rebuild historic research pier 2
Complete cell culture media with cytokines...
Request Info...
Contains 0.2 g/L EDTA4Na in phosphate-buffered saline....
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C ... Cl N O 6 ,M.W.= ... ,Solution: Clear (2% in DMF) ,Biological ... and M13 ,Elemental Analysis: Agrees with ...
Biology Products: